Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05043051
Other study ID # 13705
Secondary ID 2R01HL128393-04
Status Recruiting
Phase N/A
First received
Last updated
Start date January 14, 2022
Est. completion date July 31, 2025

Study information

Verified date March 2024
Source University of Oklahoma
Contact Xichun Yu
Phone 405-271-5896
Email xichun-yu@ouhsc.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to test the hypothesis that an antibody-mediated autoimmune reaction will cause symptoms of autonomic dysfunction in some patients with postural tachycardia syndrome (POTS). The investigators further hypothesize that electrical stimulation of the vagus nerve will improve POTS symptoms, autoimmunity and inflammation.


Description:

The present study is designed to test the hypothesis that muscarinic autoantibody-mediated parasympathetic dysfunction contributes to the pathogenesis of POTS, and that parasympathetic (vagal) stimulation improves POTS symptoms, autoimmunity and inflammation. Define and determine the prevalence, burden, and clinical significance of muscarinic autoantibodies in a well-phenotyped cohort of POTS patients with and without gastroparesis and a matched cohort of healthy control subjects. Evaluate the impact of vagal stimulation on antibody suppression, inflammatory inhibition, and symptom improvement in POTS patients. Non-invasive transcutaneous stimulation of the auricular branch of the vagus nerve (tragus stimulation) will be used to increase parasympathetic activity.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date July 31, 2025
Est. primary completion date February 28, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - 18-80 years old, female or male - Either healthy control or individual with postural tachycardia syndrome (POTS) defined as heart rate increase >30 bpm from supine within 10 min of standing, in the absence of orthostatic hypotension (>20/10 mmHg fall in blood pressure), with chronic symptoms (>6 months), and in the absence of other acute cause of orthostatic tachycardia - Able and willing to provide informed consent - Understand and be able to comply with the study procedures and restrictions Exclusion Criteria: - Hypertension (>150 mmHg systolic and >100 mmHg diastolic) based on history or findings at screening - Orthostatic hypotension (consistent drop in blood pressure >20/10 mmHg with 10 min of standing) - Cardiovascular disease, such as myocardial infarction within 6 months - History or presence of significant immunological or hematological disorders - History of vagotomy - Currently pregnant women or women planning on becoming pregnant = 3 months - Inability to comply with the protocol - Patients with active implants (such as a cardiac pacemaker, or a cochlear implant) Healthy control subjects will be healthy, non-smoking and on no chronic medications at the time of the study. Healthy control subjects will be group-matched to the POTS patients for age and gender.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Vagal stimulation
Vagal stimulation
Sham stimulation
Sham vagal stimulation

Locations

Country Name City State
United States Oklahoma Clinical and Translational Science Institute Oklahoma City Oklahoma

Sponsors (2)

Lead Sponsor Collaborator
University of Oklahoma National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Heart rate variability Average of heart rate variability during the posture test 5 minute
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03124355 - Vagal Stimulation in POTS Phase 1
Recruiting NCT04310644 - Autonomic Small Fiber Neuropathy and Ehlers Danlos Syndromes - Prospective Study and Registry
Completed NCT03253120 - Alterations of Attention in POTS Depending on Body Position and Hydration N/A
Completed NCT03919773 - IVIG (Gamunex-C) Treatment Study for POTS Subjects Phase 1/Phase 2
Active, not recruiting NCT01988883 - Modafinil and Cognitive Function in POTS Early Phase 1
Active, not recruiting NCT01000350 - Intravenous (IV) Saline and Exercise in Postural Tachycardia Syndrome (POTS) N/A
Recruiting NCT00409435 - A Study of Pyridostigmine in Postural Tachycardia Syndrome Phase 2
Completed NCT00770484 - Effect of Exercise in OI N/A
Completed NCT00581022 - Objective Sleep Disturbances in Orthostatic Intolerance
Terminated NCT00748228 - Dopamine in Orthostatic Tolerance N/A
Active, not recruiting NCT05630040 - VNS for Long-COVID-19 N/A
Recruiting NCT04632134 - Long-term Effects of Transcutaneous Vagal Nerve Stimulation on Postural Orthostatic Tachycardia Syndrome (POTS) N/A
Completed NCT00685919 - Peripheral Dopamine in Postural Tachycardia Syndrome Phase 2/Phase 3
Completed NCT00061009 - Hypnosis in Autonomic Function N/A
Recruiting NCT05618054 - Periaqueductal Gray-vagus Nerve Interface Malfunction Explain the Natural History With Its Numerous Co-morbidities? N/A
Completed NCT01366963 - Cognitive Dysfunction in Postural Tachycardia Syndrome N/A
Recruiting NCT05107635 - Inappropriate Sinus Tachycardia Registry
Terminated NCT02154009 - Clinical Autonomic Disorders: A Training Protocol
Completed NCT03602482 - Standing Cognition and Co-morbidities of POTS Evaluation N/A
Completed NCT02167412 - EEG Characteristics in Youth POTS and/or Syncope